SEARCH LISTED COMPANY
ANY AUS OR NZ COMPANY
SEARCH PRIVATE COMPANY
SEARCH FUNDS
Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
| FROM | TO | |
|---|---|---|
| PRESCIENT THERAPEUTICS LIMITED | 15/12/2014 | |
| VIRAX HOLDINGS LIMITED | 24/03/1997 | 15/12/2014 |
| RANCOO LIMITED | 24/03/1997 |
Level 5, 126 Philip Street Sydney NSW 2000 GPO Box 5193 Sydney NSW 2001
Tel : 1300 288 664 or +61 2 9698 5414The suspension of trading in the securities of Prescient Therapeutics Limited will be lifted from the commencement of trading on Tuesday, 26 May 2020, following the release by PTX of an announcement regarding a material licence agreement. | 26/05/2020 |
PTX obtains global, exclusive licence from University of Pennsylvania for an innovative universal immune receptor platform for the development of innovative cell therapies. PTX also has a global, non-exclusive licence from Oxford University to use the novel molecular binding system that is complementary with the Penn technology. PTX plans to incorporate the technologies from Penn, Oxford University and other assets, to build a universal chimeric immune receptor platform termed OmniCAR for next generation cell therapy product development. OmniCAR will enable in-house development of next generation engineered cell therapies and create opportunities for collaboration and business development in the cell therapy field for PTX. PTX's long term goal is to harness OmniCAR's innate adaptability and control to develop novel cell therapy products for new indications, and improve the cost, time and of effectiveness of delivering cell therapy products. | 26/05/2020 |
The securities of Prescient Therapeutics Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of PTX, pending the release of an announcement regarding a material licence agreement. | 25/05/2020 |
name changed from Virax Holdings Limited | 15/12/2014 |
we understand that on or about this date the company consolidated its shares 1 for 20 | 02/12/2014 |
I have a Transaction Confirmation Statement indicating my shares have been consolidated on a 1 to 10 basis, with a closing balance of 8400. Can I sell this so any loss made can be registered in my name for tax purposes? | 16/09/2019 17:10:46 |
consolidation of shares leaves me with only 156 shares of PTX nnDo you purchase small parcels for a fee so I can use the loss for tax purposes? | 11/04/2017 16:04:17 |
Purchases Sales
| DATE | DIRECTOR | NUMBER | PRICE | AMOUNT |
|---|---|---|---|---|
| 01/05/2025 | James Campbell | 222,000 | $0.045 | $9,990.00 |
| 29/04/2025 | Melanie Farris | 250,000 | $0.047 | $11,775.00 |
| 14/03/2025 | Gavin Shepherd | 614,092 | $0.043 | $26,133.00 |
| 30/09/2024 | Gavin Shepherd | 235,908 | $0.040 | $9,435.00 |
| 26/03/2019 | James Campbell | 178,125 | $0.056 | $9,968.00 |
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| James McDonnell | CEO | 20/01/2025 |
| Gavin Shepherd | Independent Director | 04/07/2024 |
| Ellen Feigal | Independent Director | 15/05/2023 |
| Melanie Farris | Independent Director | 10/04/2025 |
| James Campbell | Non Exec Director | 28/11/2014 |
| Allen Ebens | Non Exec Director | 01/06/2020 |
| Melanie Leydin | Company Secretary |
Date of first appointment, title may have changed.
| NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
|---|
Date of first appointment, title may have changed.
